[{"address1": "One Cavendish Place", "address2": "4th Floor", "city": "London", "zip": "W1G 0QF", "country": "United Kingdom", "phone": "44 33 3023 7300", "website": "https://www.mereobiopharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Denise Vera Scots-Knight Ph.D.", "age": 65, "title": "Co-Founder, CEO & Executive Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 890562, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles Edward Sermon", "age": 55, "title": "Co-Founder, General Counsel, Business Development & Company Secretary", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 625786, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Fox CPA", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 569768, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John P. Richard M.B.A.", "age": 67, "title": "Co-Founder & Chief Business Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John A. Lewicki Ph.D.", "age": 72, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jackie  Parkin", "age": 66, "title": "Senior VP & Therapeutic Head", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Hughes-Wilson", "age": 53, "title": "Chief of Patient Access & Commercial Planning", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Suba  Krishnan", "age": 59, "title": "Senior Vice President of Clinical Development", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bo  Kara", "title": "Senior VP and Head of Pharmaceutical Development & CMC", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.41, "open": 2.41, "dayLow": 2.2801, "dayHigh": 2.4766, "regularMarketPreviousClose": 2.41, "regularMarketOpen": 2.41, "regularMarketDayLow": 2.2801, "regularMarketDayHigh": 2.4766, "payoutRatio": 0.0, "forwardPE": -76.666664, "volume": 867534, "regularMarketVolume": 867534, "averageVolume": 1244296, "averageVolume10days": 1031330, "averageDailyVolume10Day": 1031330, "bid": 2.27, "ask": 2.33, "bidSize": 3, "askSize": 3, "marketCap": 365700000, "fiftyTwoWeekLow": 2.225, "fiftyTwoWeekHigh": 5.02, "fiftyDayAverage": 2.7214, "twoHundredDayAverage": 3.666, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1720801536, "profitMargins": 0.0, "floatShares": 506728824, "sharesOutstanding": 155146000, "sharesShort": 6026904, "sharesShortPriorMonth": 7260518, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0388, "heldPercentInsiders": 0.01017, "heldPercentInstitutions": 0.74433, "shortRatio": 3.82, "shortPercentOfFloat": 0.046, "impliedSharesOutstanding": 140243008, "bookValue": 0.393, "priceToBook": 5.852417, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -43253000, "trailingEps": -0.3, "forwardEps": -0.03, "enterpriseToEbitda": -38.127, "52WeekChange": -0.32551318, "SandP52WeekChange": 0.06429911, "quoteType": "EQUITY", "currentPrice": 2.3, "targetHighPrice": 10.037536, "targetLowPrice": 5.994046, "targetMeanPrice": 7.5160236, "targetMedianPrice": 7.0269217, "recommendationMean": 1.25, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 69802000, "totalCashPerShare": 0.09, "ebitda": -45134000, "totalDebt": 6429000, "quickRatio": 5.242, "currentRatio": 5.399, "debtToEquity": 10.545, "returnOnAssets": -0.39992002, "returnOnEquity": -0.7758, "freeCashflow": -28889124, "operatingCashflow": -32834000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "MREO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1556112600000, "postMarketChangePercent": -1.30435, "postMarketPrice": 2.27, "postMarketChange": -0.03, "regularMarketChange": -0.11000013, "regularMarketDayRange": "2.2801 - 2.4766", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1244296, "fiftyTwoWeekLowChange": 0.07500005, "fiftyTwoWeekLowChangePercent": 0.033707887, "fiftyTwoWeekRange": "2.225 - 5.02", "fiftyTwoWeekHighChange": -2.72, "fiftyTwoWeekHighChangePercent": -0.5418327, "fiftyTwoWeekChangePercent": -32.55132, "earningsTimestamp": 1742988636, "earningsTimestampStart": 1742988636, "earningsTimestampEnd": 1742988636, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.3, "epsForward": -0.03, "epsCurrentYear": -0.03857, "priceEpsCurrentYear": -59.631836, "fiftyDayAverageChange": -0.42140007, "fiftyDayAverageChangePercent": -0.15484679, "twoHundredDayAverageChange": -1.3659999, "twoHundredDayAverageChangePercent": -0.3726132, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "shortName": "Mereo BioPharma Group plc", "longName": "Mereo BioPharma Group plc", "marketState": "CLOSED", "regularMarketChangePercent": -4.5643206, "regularMarketPrice": 2.3, "corporateActions": [], "postMarketTime": 1743205880, "regularMarketTime": 1743192001, "exchange": "NCM", "messageBoardId": "finmb_307970474", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Mereo BioPharma", "trailingPegRatio": null, "__fetch_time": "2025-03-29"}]